- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03742232
Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen.
A Multicentre Randomized Parallel Group Phase IV Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Palermo, Italy
- Ismett
-
Rozzano, Italy, 20089
- Humanitas research hospital
-
-
Italia
-
Aviano, Italia, Italy
- Centro Di Riferimento Oncologico
-
Brescia, Italia, Italy
- Fondazione Poliambulanza
-
Roma, Italia, Italy
- Nuovo Regina Margherita Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must provide written informed consent.
- Male and female outpatients and inpatients aged: ≥18 to ≤85 years undergoing a screening, surveillance or diagnostic colonoscopy.
Females of child-bearing potential must have a negative pregnancy test at Screening and at Visit 2 and must be practising one of the following methods of birth control and agree to continue with the regimen throughout the study period:
- Oral, implantable, or injectable contraceptives (for a minimum of three months before study entry) in combination with a condom;
- Intrauterine device in combination with a condom; Double barrier method (condom*, and occlusive cap [diaphragm or cervical/vault caps] with spermicidal foam/gel/film/ cream/suppository); *A female condom and a male condom should not be used together as friction between the two can result in either product failing.
If any female patient has a positive pregnancy test at Visit 2, they will be excluded from further participation in the study for the efficacy evaluation, i.e. they will not undergo the colonoscopy procedure. The Investigator will be required to arrange a colonoscopy procedure outside of the study.
Note: The above birth control methods do not apply to females who are postmenopausal or surgically sterile i.e. 12 months of natural (spontaneous) amenorrhea or 6 weeks' post-surgical bilateral oophorectomy with or without hysterectomy or hysterectomy, or whose sole sexual partner has had a vasectomy and has received medical assessment of the surgical success.
- Willing, able and competent to complete the entire study and to comply with instructions.
Exclusion Criteria:
- Patients with past history within last 12 months or current episode of severe constipation (requiring repeated use of laxatives/enema or physical intervention before resolution), known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.
- Patients with ongoing severe acute Inflammatory Bowel Disease (IBD).
- Patients who have had previous significant gastrointestinal surgeries, including colonic resection, sub-total colectomy, abdomino-perineal resection, de-functioning colostomy, Hartmann's procedure and defunctioning ileostomy or other similar surgeries involving structure and function of the small or large colon.
- Regular use of laxatives or colon motility altering drugs (i.e. more than 2-3 times per week) in the last 28 days prior to the Screening Visit and/or laxative use within 72 hours prior to administration of the preparation.
- Patients with active intestinal bleeding episodes
- Known glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- Known phenylketonuria.
- Known hypersensitivity to polyethylene glycols, ascorbic acid and sulfates (not including sulfa-based products) or any other component of the investigational product or comparator.
- Past history within the last 12 months or evidence of any on-going clinically relevant electrocardiogram (ECG) abnormalities (e.g. arrhythmias).
- History of uncontrolled hypertension with systolic blood pressure >170 mmHg and diastolic blood pressure >100 mmHg.
- Patients with cardiac insufficiency NYHA grades III or IV.
- Patients with severe renal insufficiency.
- Patients with known liver disease of grades B and C according to the Child Pugh classification.
- Patients suffering from dehydration at screening as evaluated by the Investigator from physical examination.
- Patients with pre-existing clinically significant electrolyte abnormalities, or dehydration.
- Patients with impaired consciousness that might predispose them to pulmonary aspiration.
- Patients undergoing colonoscopy for foreign body removal and/or decompression.
- Patients who are pregnant or lactating, or intending to become pregnant during the study.
- Clinically relevant findings on physical examination based on the Investigator's judgment.
- History of drug or alcohol abuse within the 12 months prior to dosing.
- Concurrent participation in an investigational drug or device study or participation within three months of study entry.
- Patients who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures, e.g. cognitively impaired, debilitated or fragile patients.
- Patients who are ordered to live in an institution on court or authority order.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PLENVU
PLENVU® supplied as two powder-for-oral-solution formulations.
One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.
|
PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes. PLENVU® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy). |
Active Comparator: SELG-ESSE
SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.
|
SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes. SELG-ESSE® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bowel cleansing efficacy
Time Frame: 1 Day of colonoscopy
|
To evaluate the overall bowel cleansing efficacy of 2-day split-dosing with PLENVU compared to a 2-day split-dosing regimen with SELG-ESSE®, graded according to the Boston Bowel Preparation Scale (BBPS) in patients undergoing screening, surveillance or diagnostic colonoscopy.
|
1 Day of colonoscopy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Polip Detection Rate
Time Frame: 1 Day of colonoscopy
|
To assess the overall Polip Detection Rate with PLENVU compared to SELG-ESSE
|
1 Day of colonoscopy
|
Adenoma Detection Rate
Time Frame: 1 Day of colonoscopy
|
To assess the overall Adenoma Detection Rate with PLENVU compared to SELG-ESSE;
|
1 Day of colonoscopy
|
Adverse events
Time Frame: 4 days after colonscopy
|
To assess the incidence of adverse events in PLENVU group comparing SELG-ESSE arm
|
4 days after colonscopy
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2063
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colon Adenoma
-
Western Sydney Local Health DistrictRecruitingColon Cancer | Colon Adenoma | Adenoma ColonAustralia
-
Hospital da Senhora da OliveiraCompletedColon Cancer | Colon Adenoma | Colon Polyp | Colon Rectal CancerPortugal
-
University of British ColumbiaRecruitingColon Adenoma | Colon Polyp | Colon LesionCanada
-
Satisfai Health, Inc.Meditrial USA Inc.Not yet recruitingPolyp of Colon | Colon Adenoma | Adenoma ColonUnited States, Italy, Canada
-
Verily Life Sciences LLCCompletedColon Adenoma | Colon Polyp | Colon LesionUnited States, Israel
-
The University of Hong KongTan Tock Seng Hospital; Institute of Gastroenterology and Hepatology, VietnamCompletedColon Adenoma | Colon PolypChina, Singapore, Vietnam
-
Milton S. Hershey Medical CenterCompletedColon Cancer | Colon Adenoma | Colon PolypUnited States
-
London North West Healthcare NHS TrustCompletedAdenoma Colon | Serrated AdenomaUnited Kingdom
-
Instituto Portugues Oncologia de Lisboa Francisco...Recruiting
-
Western Sydney Local Health DistrictRecruitingColon Adenoma | Colon PolypAustralia
Clinical Trials on PEG3350
-
Braintree LaboratoriesCompletedConstipationUnited States
-
Rabin Medical CenterWithdrawn
-
John LenehanNot yet recruitingUnresectable or Metastatic Advanced Pancreatic Ductal AdenocarcinomaCanada